Cargando...

免疫检查点抑制剂在驱动基因阳性晚期非小细胞肺癌中的应用进展

With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Zhongguo Fei Ai Za Zhi
Formato: Artigo
Lenguaje:Inglês
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8143967/
https://ncbi.nlm.nih.gov/pubmed/33819969
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2021.101.04
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!